2I-BFM-SG.Protocol and committee progress report,p10,BFM-Austria-Germany-Switzeri-and,ALL-BMF2000[M].Prelimi nary report,2003
3Naito K,Takeshita A,Matsui H,et al.Multidrug resistance(MDR)-related protein 1 (MRP1) and lung resistance protein (LRP)are not the main drug resistance mechanisms of gemtuzumab ozogamicin(CMA-676)in AML[J].Hematol J,2003,3(9):1048
4Matsui H,Takeshita A Naito K,et al.Reduced effect of gemtuzumab ozogamicin(CMA-676)on Pglycoprotein and-or CD34 positive leukemia cekks and its restoration by multidrug resistance modifiers[J].Leukemia,2002,16(5):813
2Faded S, Gandhi V, Obrien s, et al. Result of a phase 1 - 2 study of clofarabine in combination with Ara. C in relapsed and refractory acute leukemia [ J ]. Blood, 105 (2) :940 - 947.
3LARSON R A, SIEVERS E L ' STADTMAUER E A, et al. Final re- port of the eficacy and safety of gemtuzumab ozogamieln (Mylotarg)in patients with CD33 - positive acute myeloid leukemia in firs [ recur- renee [ J ]. Cancer,2005,104 (7) : 1442 - 1452.
4Marcucci G, Moser B, BlumW ,'et al. A Phase Ⅲ randomized trial of intensive induction and consolidation chemotherapy oblimerson, a pro-apoptotic Bcl -2 antisense oligonueleotide in afttreated acute myeloid leukemia patients > 60 years old [J]. J ClinOncol, 2007,25 ( 18 Suppl ) :7012.
5MARCUCCI G,BYRD J C ,DAI G,et al. Phase 1 and pharmacodyna- mic studies of G3139 ,a Bc1-2 antiscnse oligonucleotide,in combina- tion with chemotherapy in refractory or relapsed acute leukemia [ J]. Blood,2003,101 (2) :425 -432.
